MedTrace Logo

The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)

NCT00906035 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-09-05

Study results available
· View outcomes & findings →

Summary

This research study will evaluate the effects of aspirin and dipyridamole alone and in combination on the blood flow in the vessels of the legs. We will examine how these medications are able to inhibit the clotting of platelets in the vessels of patients with PAD, and thereby affect the blood flow in the legs. Platelets are cells in the blood that have the ability to adhere to each other to form clots.

Conditions

  • Peripheral Arterial Disease

Interventions

DRUG

Dipyridamole 200mg and Aspirin 25mg bid:

All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.

DRUG

Dipyridamole 200 mg bid

All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.

DRUG

Aspirin 25 mg bid

All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.

Sponsors & Collaborators

Principal Investigators

  • Garret A FitzGerald, MD · University of Pennsylvania

  • Emile R Mohler, MD · University of Pennsylvania

  • Tilo Grosser, MD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2010-03-31
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00906035 on ClinicalTrials.gov